iM Securities raises Hanmi Pharmaceutical target price to 650,000 won
In short
iM Securities raised its target price for Hanmi Pharmaceutical to 650,000 won from 600,000 won on October 8 and kept a Buy rating, Chosun Ilbo reported. The broker cited newly reflected pipeline value for the obesity drug candidate HM17321 and a possible upfront licensing payment in the third quarter. The stock's previous close was 534,000 won.
Read the full story 1 min read
iM Securities on October 8 raised its target price for Hanmi Pharmaceutical from 600,000 won to 650,000 won and kept its Buy rating, Chosun Ilbo reported. The broker said it newly reflected the pipeline value of the obesity drug candidate HM17321 and that Hanmi could receive an upfront technology-transfer payment in the third quarter of this year. The stock's previous closing price was 534,000 won. [ 2 , 3 ]
iM Securities analyst Jung Jae-won said HM17321 was developed using Hanmi's own artificial intelligence, according to Chosun Ilbo, and the Korea Economic Daily headlined the note as validating the value of an AI-designed obesity drug candidate. Newsis reported the note under a headline citing expectations that Hanmi could secure market share in obesity treatments. [ 1 , 2 , 4 ]
Why it matters
The revision reflects how a broker values Hanmi Pharmaceutical's obesity drug pipeline, according to the business outlets that covered it. Newsis framed the call around expectations that Hanmi could secure a share of the obesity treatment market.
Key facts
- iM Securities raised its target price for Hanmi Pharmaceutical to 650,000 won. [ 2 , 3 , 4 ]
- The previous target price was 600,000 won. [ 2 , 3 ]
- iM Securities kept its Buy investment rating. [ 2 , 3 ]
- The revision newly reflects the pipeline value of obesity drug candidate HM17321. [ 2 , 3 ]
- iM Securities said Hanmi could receive an upfront technology-transfer payment in the third quarter of this year. [ 2 , 3 ]
- Hanmi Pharmaceutical's previous closing price was 534,000 won. [ 2 , 3 ]
- The Korea Economic Daily headline described the candidate as an obesity drug designed with AI. [ 1 ]
Confirmed by several sources
Still unclear
- Details of the technology-transfer deal behind the expected upfront payment. The documents mention the possible third-quarter upfront payment but do not describe the deal in this event's coverage.
- The full reasoning of iM Securities analyst Jung Jae-won. The quote about HM17321 being designed with Hanmi's own artificial intelligence is cut off in the available summaries.
What local media are saying
Timeline, local time
- Korea Economic Daily reports that iM Securities raised its target price, citing the AI-designed obesity drug candidate. [ 1 ]
- Chosun Ilbo reports the target was raised from 600,000 won to 650,000 won with a Buy rating kept. [ 2 , 3 ]
- Newsis reports the 650,000 won target and expectations for obesity treatment market share. [ 4 ]